Loading…
← CockpitCompetitor Analysis › 3349.T COSMOS Pharmaceutical CorporationOpen in the cockpit ↗

COSMOS Pharmaceutical Corporation3349.TCompetitor analysis, valuation and peers

Japan · JPY·Health Care›Medical Distributors

Drugstore chain based in Kyushu, selling pharmaceuticals, cosmetics and daily goods at discount prices.

≈ A Japanese CVS/Walgreens-style discount drugstore chainMomentum neutral 55
Mkt cap
$3.21B
US dollars, full cap
Free float
52%
of shares outstanding
$/day
$19.8M
20-day average traded
Fwd P/E
15.9×
forward earnings
ROIC−WACC
+4.3 pp
WACC 5.0%
Hurdle
n/a
no reverse DCF
Next earnings
51 days
8 Jan 2027
Close · JPY¥6,371
1D-2.7%
1W+2.2%
1M-1.4%
3M-3.2%
6M+1.6%
YTD-19.8%
1Y-8.7%
ATR %3.0%
52w lowhigh21.6% off high

What COSMOS Pharmaceutical does

Drugstore chain based in Kyushu, selling pharmaceuticals, cosmetics and daily goods at discount prices.

Draws shoppers with everyday low prices on groceries and daily goods, accepting thin margins on food, and earns more on medicines, cosmetics and pharmacy dispensing. It has expanded from its Kyushu base into western Japan.

In one line: A Japanese CVS/Walgreens-style discount drugstore chain.

Products and services

  • Drugstore retail stores
  • Pharmacy dispensing

Customers

  • Consumers in Kyushu and expanding regions

Where it sits in the supply chain

  • Consumer retail
  • Drugstore retail
  • Pharmacy, cosmetics, daily necessities…

What could go right

  • Store count growth
  • Aging population pharmacy demand

What could go wrong

  • Drugstore price competition
  • Drug price revisions

Moat: narrow (scale, cost advantage, distribution). Discount pricing scale and dense store network in its home Kyushu market.

Headquarters: Kumamoto, Japan · Founded: 1979 · Employees: 5,984

Named competitors

COSMOS Pharmaceutical at a glance

Size COSMOS Pharmaceutical (3349.T) is a Japan Health Care company (Medical Distributors) with a market value of $3.21B, the 346th largest of 1,370 Japan companies the cockpit tracks. Shares closed at ¥6,371 on 18 Nov 2026.

Performance Over six months the shares gained 1.6%, against +7.9% for the median peer and -1.4% for the Japan market (cap-weighted) — 9th lowest of 21 in its peer set.

Growth Revenue grew 9.0% over the last twelve months (peer median +6.0%); the operating margin is 3.8% (peer median 3.0%).

Valuation It trades at 15.9× forward earnings against a peer median of 15.8× (8th most expensive of 16).

Capital Return on invested capital runs 4.3 points above its cost of capital (5.0% WACC).

Next results Next results expected around 8 Jan 2027 (exchange calendar; dates can move).

Relative performance

10011021 May 202621 Aug 202618 Nov 2026Peer median 1093349.T 103
Six months, rebased to 100: COSMOS Pharmaceutical against the median of its 20 peers (local-currency closes).

COSMOS Pharmaceutical financials

Reported figures in JPY; fiscal year ends 2026-05-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue¥1.11T¥1.10T¥1.01T¥965B¥828B
Revenue growth—+9%+5%+17%—
Gross profit¥235B¥207B¥213B¥170B¥153B
EBITDA¥68.0B¥66.9B¥62.6B¥51.4B¥47.5B
Net income¥32.1B¥32.0B¥31.0B¥24.5B¥23.8B
Free cash flown/a-¥11.7B-¥859M-¥635M¥7.80B
Capital expendituren/a¥70.5B¥53.3B¥55.8B¥46.6B
Total debt¥68.5B¥78.5B¥50.0B¥34.1B¥18.2B

Quarterly statements and history in the cockpit →

COSMOS Pharmaceutical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+20%+40%-10%0%+10%AMP27847459ASKER0089306009989987GALEDKSH81291099RDC33606005877476HSICDOCM3015846007136033683349.T6-month return →1-month return →
Up and to the right = strong over both horizons. COSMOS Pharmaceutical is the large dot.

Fundamentals: revenue growth against valuation

0%+5%+10%10×20×AMP27847459ASKER6009989987GALEDKSH81291099336060058774766033683349.TRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. COSMOS Pharmaceutical is the large dot.

COSMOS Pharmaceutical competitors and peer comparison

Head to head with its named competitors (3349.T vs 9989.T vs 3088.T vs 7649.T)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
COSMOS Pharmaceutical 3349.T$3.21B+2%+9%4%15.9×n/a
Sundrug 9989.T$3.07B+10%+4%6%14.9×-7.3%
MatsukiyoCocokara & 3088.T$7.51B+29%+6%8%19.5×-4.8%
Sugi 7649.T$3.46B-9%+9%5%17.9×-9.0%
Kusuri No Aoki 3549.T$2.98B+29%+13%5%22.2×4.3%
Genky DrugStores 9267.T$728M+3%+8%5%13.9×n/a
Create SD 3148.T$1.32B+3%+9%5%n/a-11.5%

How COSMOS Pharmaceutical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

COSMOS Pharmaceutical against its 20 peers (data as of 18 Nov 2026)
Measure3349.TPeer medianRank in peer set
1-month return-1.4%+1.8%7th lowest of 21
6-month return+1.6%+7.9%9th lowest of 21
Distance from 52-week high-21.6%-14.3%5th lowest of 21
Revenue growth (TTM)+9.0%+6.0%5th highest of 21
Operating margin3.8%3.0%9th highest of 21
Forward P/E15.9×15.8×8th most expensive of 16
ROIC minus cost of capital+4.3 pp+1.6 pp4th highest of 21
EV / EBITDA8.0×12.8×2nd cheapest of 6
Net debt / EBITDA0.4×0.9×7th least indebted of 15

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
COSMOS Pharmaceutical 3349.TJapan$3.21B+2%+9%4%15.9×n/an/a
Amplifon AMP.MIItaly$3.39B+8%0%10%17.0×6.8%+9.8%
Alfresa 2784.TJapan$2.81B-3%+4%1%18.4×-8.4%+3.5%
MEDIPAL 7459.TJapan$3.70B+15%+4%1%12.5×-7.2%+3.5%
Asker Healthcare ASKER.STSweden$2.69B-14%+12%7%24.8×4.7%+12.7%
Hanmi Science 008930.KSSouth Korea$2.58B+48%+6%4%n/a26.0%+9.6%
Jointown Pharmaceutical 600998.SSChina$3.99B+7%+9%2%11.8×0.2%+7.8%
Suzuken 9987.TJapan$2.36B+8%+5%1%15.8×-10.4%+3.2%
Galenica GALE.SWSwitzerland$5.31B+8%+6%5%23.9×7.0%+3.5%
DKSH DKSH.SWSwitzerland$5.99B+24%-1%3%21.8×-1.2%+0.6%
Toho 8129.TJapan$1.64B-5%+4%1%22.2×-4.6%+5.1%
Sinopharm 1099.HKHong Kong$6.74B0%+3%3%6.2×-7.3%+4.0%
Redcare Pharmacy RDC.DEGermany$1.50B+53%+19%0%n/an/an/a
Ship Healthcare 3360.TJapan$1.38B+19%+6%3%14.6×-14.5%+7.6%
Shinva Medical Instrument 600587.SSChina$1.10B-10%+6%5%13.4×-6.9%+1.2%
AS ONE 7476.TJapan$1.10B+25%+10%12%18.4×0.0%+6.3%
Henry Schein HSICUnited States$9.47B+17%+6%6%14.7×10.2%+5.4%
DocMorris DOCM.SWSwitzerland$1.08B+169%+11%-8%n/an/an/a
Shanghai C and D INNOSTIC Medical Technology 301584.SZChina$1.06B-33%+8%3%n/a-2.7%+17.9%
Nanjing Pharmaceutical 600713.SSChina$999M-2%+3%2%n/an/an/a
Guangxi LiuYao 603368.SSChina$975M+1%+2%5%9.5×-9.7%+6.0%

Questions

Who are COSMOS Pharmaceutical's main competitors?
Named competitors: Sundrug (9989.T), Welcia Holdings (private or unlisted), Matsumotokiyoshi Holdings (3088.T), Sugi Holdings (7649.T), Kusuri no Aoki Holdings (3549.T), Genky DrugStores (9267.T). The cockpit's measured peer set (industry) also includes Amplifon (AMP.MI), Alfresa (2784.T), MEDIPAL (7459.T), Asker Healthcare (ASKER.ST), Hanmi Science (008930.KS), Jointown Pharmaceutical (600998.SS).
Is COSMOS Pharmaceutical expensive compared with its peers?
On forward p/e it trades at 15.9× against a peer median of 15.8×, 8th most expensive of 16 in its peer set.
How has COSMOS Pharmaceutical stock performed?
Over six months to 18 Nov 2026 the shares returned +1.6% against +7.9% for the median peer; over one year -8.7%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.